Article

Welcome to UCD ChestHealth!

Author(s):

David Tom Cooke, MD, FCCP, FACS

In Partnership With:

Welcome to UCD ChestHealth, the official blog of UC Davis Thoracic Surgery.

Welcome to UCD ChestHealth, the official blog of UC Davis Thoracic Surgery. This exciting new outlet, the first of its kind for a UC Davis Health System clinical service, will allow patients, physicians, students, residents, allied health professionals and anyone else who is interested or curious to learn about what we do and the important and not so publicized disease processes that affect thousands of individuals each day such as Lung Cancer, Esophageal Cancer, Emphysema/COPD and Hyperhidrosis.

Most of all, this blog will help answer that age old question “What is Thoracic Surgery?” My mother asks me that question all of the time! So feel free to comment, enjoy, and please suggest content. You can contact or follow us on twitter: @UCD_ChestHealth or email us thoracic.surgery@ucdmc.ucdavis.edu.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Related Content
Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

David R. Gandara, MD, chief medical officer, International Society of Liquid Biopsy; co-director, Center for Experimental Therapeutics in Cancer, senior advisor to the director, University of California Davis Comprehensive Cancer Center; adjunct clinical professor, Translational and Clinical Research Program, University of Hawaii Cancer Center
October 28th 2024

Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD

Lung Cancer
November 19th 2024

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10